Literature DB >> 9031616

Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms.

T Budak-Alpdoğan1, Z Demirçay, O Alpdoğan, H Direskeneli, T Ergun, M Bayik, T Akoğlu.   

Abstract

Two patients with chronic myelogenous leukemia (CML) who developed characteristic features of Behçet's disease (BD) during alpha-interferon (IFN-alpha) treatment and another patient who had a diagnosis of BD preceding CML are presented. In the first two patients, features of BD appeared 6 months after the initiation of IFN-alpha treatment: they included recurrent oral aphthae, genital ulceration, arthritis, folliculitis, and a positive skin pathergy test. The third patient, however, had a diagnosis of Behçet's disease 4 years before diagnosis of Philadelphia-positive CML. We prospectively examined the skin pathergy reaction in a group of patients with CML, multiple myeloma, and hairy cell leukemia both before and after IFN-alpha treatment and found two additional patients with CML who developed a positive skin pathergy test following IFN-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9031616     DOI: 10.1007/s002770050255

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  Rheumatologic manifestations of benign and malignant haematological disorders.

Authors:  Vinod Ravindran; Parameswaran Anoop
Journal:  Clin Rheumatol       Date:  2011-06-23       Impact factor: 2.980

Review 2.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

3.  Panuveitis simulating ocular Behçet's in cases of chronic myelogenous leukaemia in remission.

Authors:  Rohan Chawla; Koushik Tripathy
Journal:  BMJ Case Rep       Date:  2017-11-23

Review 4.  Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature.

Authors:  Soner Senel; Emin Kaya; Ismet Aydogdu; M Ali Erkurt; Irfan Kuku
Journal:  Rheumatol Int       Date:  2006-01-11       Impact factor: 2.631

Review 5.  Behçet's disease and comorbidity: internal case reports and literature review.

Authors:  Zemfira Alekberova; Vadim Gorodetskiy; Fatima Izmailova; Stefka Radenska-Lopovok; Elnura Talybova; Margarita Evsikova; Nikolai Timoshin; Evgeni Nasonov
Journal:  Rheumatol Int       Date:  2015-02-13       Impact factor: 2.631

6.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

7.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.